Carisma Therapeutics Showcases Innovative Research at SITC
Carisma Therapeutics' Significant Contributions at SITC 2024
Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, is poised to make waves at the Society for Immunotherapy of Cancer (SITC) this year. The event is eagerly anticipated in the immuno-oncology community and Carisma is set to present innovative findings that could reshape treatment approaches for cancer.
Key Highlights of Poster Presentations
Details about the poster presentations reveal major advancements that Carisma has achieved in immunotherapy. The company focuses on creating unique therapies that utilize engineered macrophages and monocytes, which play essential roles in the body’s immune response against cancer.
First Presentation: Novel Anti-GPC3 CAR-M
One of the standout presentations is titled "Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma." This study emphasizes the promising results from preclinical trials, showcasing the potential of this CAR therapy in targeting specific cancer cells.
Second Presentation: First-in-Human Study of Anti-HER2 CAR
Another notable presentation discusses the "Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors." This innovative approach emphasizes autologous cell therapy, underscoring the trend towards personalized medicine in oncology.
Event Details and Accessibility
SITC 2024 will encompass significant sessions where Carisma's findings will be shared. Attendees can find their posters located at the Exhibit Halls A and B at the George R. Brown Convention Center, and following the presentation, all materials will be accessible through the "Publications" section on Carisma's official website.
About Carisma Therapeutics
Carisma Therapeutics is noted for its commitment to transforming cancer treatment through its innovative cell therapy platform. Utilizing engineered macrophages and monocytes, the company aims to pioneer immunotherapies designed to tackle serious diseases more effectively.
Investors and Media Relations
For stakeholders interested in further insights, Carisma maintains open channels through head of investor relations, Shveta Dighe, who can be contacted directly. Additionally, Julia Stern serves as the media contact, ensuring that inquiries are addressed promptly.
Frequently Asked Questions
What are the key focuses of Carisma Therapeutics?
Carisma is dedicated to developing innovative immunotherapies using its proprietary macrophage and monocyte cell engineering platform.
Where will Carisma present its research?
The research will be presented at the Society for Immunotherapy of Cancer (SITC) event held in Houston's George R. Brown Convention Center.
When can we view the posters presented?
The posters will be available online at Carisma's website in the Publications section following the event.
How does Carisma's therapy platform work?
The platform involves creating engineered immune cells, including macrophages and monocytes, to enhance the immune response against cancer.
Who can I contact for investor-related inquiries?
Investors can reach out to Shveta Dighe, the head of investor relations, for more details.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Bonduelle Introduces Strategic Transformation Plan for Growth
- Amazon Drought Reaches Historic Low, Threatening Wildlife and Trade
- Investors to Participate in Stellantis Class Action Lawsuit
- Strong Jobs Report Signals Future Rate Cuts for Fed
- Portugal Stock Market Update: Key Movements and Trends Today
- Exploring Promising Stocks to Watch Beyond Tesla's Limelight
- IAT Community: Empowering Investors Through Education
- Smart Savings Strategies for Financial Wellness in Life
- Unibail-Rodamco-Westfield Supervisory Board Updates and Changes
- Bonduelle Unveils Three-Year Transformation Strategy and Gains
Recent Articles
- Important Update for Symbotic Investors Facing Losses
- Celebrating China's 75-Year Transformation in Development
- GAIL and AM Green Collaborate on Major Renewable Energy Initiative
- Experience the Excitement of Hatchimals Alive with Jason Kelce
- Class Action Alert for Spire Investors: Know Your Rights Now
- Warren Buffett's Strategic Moves with Berkshire Hathaway's Stock
- HotelPlanner Extends Partnership with USA Archery Events
- Significant Growth Anticipated in Data Monetization Sector
- Job Growth Surges as Economy Shows Resilience in Market Rally
- SG DevCo Implements Strategic 1-for-20 Reverse Stock Split
- Exciting Developments with db Group and Hard Rock International
- Surging Demand for Non-Dairy Yogurt: A Market Overview
- Navigating Uber's Stock Potential: A Balancing Act Between Trends
- Exploring the Future of Serverless Computing Industry Growth
- Understanding Market Sentiment for American Electric Power
- Current Market Sentiment Surrounding Wynn Resorts and Its Stock
- Analyzing Recent Trends in MACOM Technology Short Selling
- Highlights of Recent Analyst Ratings on MINISO Group and Others
- Insights From CNBC's Latest Discussions on Top Stocks
- Russel Metals Announces Conference Call Plans for Q3 2024
- Investigation Launched on Coeur Mining Merger for Fairness
- MIA Global's Strategic Move into E-Mobility with ALYI
- Neonode's Bold Move: Ending Agreement with Redeye
- ISG Paragon Awards 2024: Honoring Innovation and Excellence
- Increasing Crude Oil Prices Amid Global Uncertainties
- Arista Networks Achieves Unprecedented Stock Milestone
- MasTec Inc Stock Hits Record High: Key Insights and Outlook
- Neonode Inc. Cuts Ties with Redeye for Financial Services
- SiTime Shares Surge to Historic Peak: What You Need to Know
- Trade Desk Achieves New Highs with Exceptional Market Growth
- Tempur Sealy Moves to Block FTC's Challenge to Mattress Firm Deal
- First Financial Bancorp Schedules Q3 2024 Results Announcement
- Victory Capital Holdings Achieves Record Stock Price Growth
- TransUnion Achieves New 52-Week Milestone Amid Growth Surge
- Celebrating 75 Years of Progress in the People's Republic
- Neonode Cancels Partnership with Redeye Amidst New Strategies
- Blue Owl Capital's Stock Surges Amid Strong Growth Metrics
- Celebrating CATIC: Recognized as a Top Workplace of 2024
- Jefferies Financial Group Reaches New Market Heights
- Positive Economic Indicators Support Stock Market Stability
- KNTK Stock Reaches New Heights: Key Metrics and Growth Insights
- Federal Reserve Adjusts Rate-Cut Strategy Following Job Surge
- Meta Unveils Movie Gen: A New Era of AI Video Creation
- Mizuho Analysts Recommend Apple Stock as Long-Term Investment
- Johnson & Johnson Ends Research on Dengue Treatment
- Tellurian Shareholders Approve $1.2B Acquisition by Woodside Energy
- U.S. Job Growth Surges: Impacts on Economy and Markets
- Understanding Altria's Current Market Challenges and Prospects
- Why SoFi Technologies Is a Strong Investment Opportunity
- IO Biotech Highlights Breakthrough Cancer Vaccine Presentations